A highlight on carbamazepine-induced adverse drug reactions in Saudi Arabia: a retrospective medical records-based study
Authors:
Open Access
- 18 May 2023
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (11) , 3177-3182
Abstract
The link between human leukocyte antigen (HLA) alleles and carbamazepine-induced cutaneous, respiratory, and gastrointestinal adverse drug reactions (ADR) has created a window of opportunity for preventing certain forms of cutaneous adverse drug reactions (cADRs); however, there is not enough data to make pharmacogenomic recommendations that can be implemented globally. The aim of this study is to assess and document carbamazepine-induced adverse reactions among prescribed Saudi/non-Saudi patients. A retrospective chart review was performed for patients who received carbamazepine (CBZ) in the period between 2016 and 2020, in the Kingdom of Saudi Arabia. Data were gathered and descriptive statistical analyses were performed on the data for the study sample. Comparisons were made using the chi-square test or independent samples’ t-test. Statistical significance was considered at p < .05. All statistical analyses were performed using IBM SPSS 21.0 (Armonk, NY; IBM Corp). Results from multivariate logistic regression analyses showed that higher likelihood of carbamazepine-induced adverse reactions was significantly associated with younger age, OR = 0.82, 95% CI (0.74, 0.90); p < 0.001. Patients who were prescribed CBZ for reasons other than epilepsy or seizures were significantly more likely to develop carbamazepine-induced adverse reactions (epilepsy vs. other; OR = 0.63, p = 0.013; seizures vs. other; OR = 0.59, p = 0.018). Gender or medication duration were not related to carbamazepine-induced adverse reactions (p > 0.05). The findings of this study are comparable with those of other studies assessing carbamazepine-associated adverse reactions in children and adults. Recommendations include genetic prescreening, educating patients and parents on the possibility of adverse reactions, and routine laboratory monitoring.Keywords
This publication has 30 references indexed in Scilit:
- Carbamazepine-induced interstitial pneumonitis associated with pan-hypogammaglobulinemiaRespiratory Medicine Case Reports, 2012
- Microscopic colitisWorld Journal of Gastroenterology, 2012
- Carbamazepine, HLA-B*1502 and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA RecommendationsPharmacogenomics, 2008
- Idiosyncratic Adverse Reactions to Antiepileptic DrugsEpilepsia, 2007
- HUMAN IN VITRO GLUTATHIONYL AND PROTEIN ADDUCTS OF CARBAMAZEPINE-10,11-EPOXIDE, A STABLE AND PHARMACOLOGICALLY ACTIVE METABOLITE OF CARBAMAZEPINEDrug Metabolism and Disposition, 2005
- Carbamazepine hypersensitivity syndrome presenting as vasculitis of the CNSJournal of Neurology, Neurosurgery & Psychiatry, 1999
- Carbamazepine induced vasculitis.Journal of Neurology, Neurosurgery & Psychiatry, 1987
- Clinical Pharmacokinetics and Pharmacological Effects of Carbamazepine and Carbamazepine-10,11-EpoxideClinical Pharmacokinetics, 1986
- Pulmonary eosinophilia associated with carbamazepine.Archives of Disease in Childhood, 1983
- Pulmonary eosinophilia and asthma associated with carbamazepine.BMJ, 1981